| Original language | English |
|---|---|
| Pages (from-to) | 1969-1971.e2 |
| Journal | Journal of Allergy and Clinical Immunology: In Practice |
| Volume | 11 |
| Issue number | 6 |
| Early online date | 28 Mar 2023 |
| DOIs | |
| Publication status | Published - Jun 2023 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, No. 6, 06.2023, p. 1969-1971.e2.
Research output: Journal article (peer-reviewed) › Journal article
TY - JOUR
T1 - Identification of Motivators and Barriers Impacting Successful Food Introduction or Reintroduction after Negative Oral Food Challenges
AU - Ditlof, Christina M
AU - Hummel, Roxanne H
AU - Wong, Sam
AU - Li, Carmen H
AU - Alexanian-Farr, Mara
AU - Zahrebelny, Slavka O
AU - Hoang, Jennifer A
AU - Hung, Lisa
AU - Upton, Julia E M
AU - Atkinson, Adelle R
AU - Asper, Maria
AU - Hummel, David
AU - Eiwegger, Thomas
N1 - Funding Information: This work has been supported by unrestricted grants from the Food Allergy and Anaphylaxis Program at the Hospital for Sick Children. Conflicts of interest: J. E. M. Upton reports grants/research support from DBV Technologies, Regeneron, CIHR, ALK-Abelló, and the SickKids Food Allergy and Anaphylaxis Program; served on the advisory board for Pfizer, Kaleo, Bausch Health, and Food Allergy Canada; received an in-kind drug donation from Novartis; and other services for Astra-Zeneca, all outside the current work. T. Elwegger reports to act as a local principal investigator for company-sponsored trials by DBV Therapeutics, and Greer Stallergens; as a subinvestigator for Regeneron and ALK-Abelló; is co-investigator or scientific lead in 3 investigator-initiated oral immunotherapy trials supported by the SickKids Food Allergy and Anaphylaxis Program; serves as an associate editor for Allergy; his laboratory received unconditional/in-kind contributions from Macro Array Diagnostics and an unrestricted grant from ALK-Abelló; holds advisory board roles for ALK-Abelló, VAMED, Nutricia/Danone, and Aimmune; and reports lecture fees from Novartis, ThermoFisher, Nutricia/Danone, Aimmune, and ALK-Abelló. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: This work has been supported by unrestricted grants from the Food Allergy and Anaphylaxis Program at the Hospital for Sick Children. Funding Information: Conflicts of interest: J. E. M. Upton reports grants/research support from DBV Technologies, Regeneron, CIHR, ALK-Abelló, and the SickKids Food Allergy and Anaphylaxis Program; served on the advisory board for Pfizer, Kaleo, Bausch Health, and Food Allergy Canada; received an in-kind drug donation from Novartis; and other services for Astra-Zeneca, all outside the current work. T. Elwegger reports to act as a local principal investigator for company-sponsored trials by DBV Therapeutics, and Greer Stallergens; as a subinvestigator for Regeneron and ALK-Abelló; is co-investigator or scientific lead in 3 investigator-initiated oral immunotherapy trials supported by the SickKids Food Allergy and Anaphylaxis Program; serves as an associate editor for Allergy; his laboratory received unconditional/in-kind contributions from Macro Array Diagnostics and an unrestricted grant from ALK-Abelló; holds advisory board roles for ALK-Abelló, VAMED, Nutricia/Danone, and Aimmune; and reports lecture fees from Novartis, ThermoFisher, Nutricia/Danone, Aimmune, and ALK-Abelló. The rest of the authors declare that they have no relevant conflicts of interest.
PY - 2023/6
Y1 - 2023/6
UR - https://www.scopus.com/pages/publications/85152692160
U2 - 10.1016/j.jaip.2023.03.040
DO - 10.1016/j.jaip.2023.03.040
M3 - Journal article
C2 - 36997121
SN - 2213-2198
VL - 11
SP - 1969-1971.e2
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 6
ER -